Reports

2021

• Drug Pricing Investigation Majority Staff Report

  • Documents

• Drug Pricing Investigation: Lost Savings: How Prohibiting Medicare Negotiation Has Cost Taxpayer

• Drug Pricing Investigation: AbbVie-Humira and Imbruvica

  • Documents 

• Drug Pricing Investigation: Industry Spending on BuyBacks, Dividends, and Executive Compensation

2020

• Drug Pricing Investigation: Celgene and Bristol Myers Squibb-Revlimid

  • Documents​​​​​​

• Drug Pricing Investigation: Teva-Copaxone 

  • Documents

• Drug Pricing Investigation: Amgen-Enbrel and Sensipar

  • ​​​​​​​Documents

• Drug Pricing Investigation: Novartis-Gleevec

  • ​​​​​​​Documents

• Drug Pricing Investigation: Mallinckrodt-H.P. Acthar Gel

  • ​​​​​​​Documents